Valion Bio evaluates sale of CDMO subsidiary after receiving unsolicited interest
Valion Bio announced that independent parties have approached it about acquiring its contract development and manufacturing organization, Velocity Bioworks. The company has engaged an investment bank to guide its board through the evaluation of possible outcomes, including a sale. Retaining production rights for its lead candidate Entolimod remains a priority, and the firm said no transaction is guaranteed.
Why it matters
The company said a sale could generate additional capital to fund Entolimod’s development and other corporate initiatives. Investors should watch for any definitive agreement, as it could affect Valion’s cash position and future earnings potential.
Key facts
- 1Valion Bio received unsolicited acquisition inquiries for its CDMO subsidiary Velocity Bioworks. tradingview.com
- 2The board has retained an investment bank to provide advice on the potential transaction. tradingview.com
- 3Retaining production rights for Entolimod and other pipeline assets is a key consideration in any sale. tradingview.com
- 4No agreement has been reached and the discussions are still preliminary. tradingview.com
- 5Valion stated there is no assurance that the talks will result in a definitive agreement. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.